AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06681740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The control group will perform a standard cardiac rehabilitation program, consisting of 16 multicomponent exercise sessions, health education, and a weekly group of psychological therapy session. The intervention group will do the same program with the addition of Inspiratory Muscle Training (IMT). The following device will be used: Power Breath model: Medic Classic. The training will be performed by adjusting the device load to 70% of the Maximum Inspiratory Pressure value, performing 1 daily training session 4 days a week of 3 sets of 10 repetitions, with a rest of 3 minutes between sets, during 8 weeks. A physical therapist will teach participants how to use the device on the first day and they will be instructed to perform it at home. They will be given a diary to record their compliance. In addition, once a week the physiotherapist will supervise the execution of the IMT by the participants.
Study NCT06681740 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory muscle training
Description: The control group will be given the same device as experimental group, but the load for all of the participants of the control group will be 5cm de H2O. This load is so low that it´s not able to induce improvement of the inspiratory musculature.
Study NCT06688032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jarlsberg cheese
Description: Jarlsberg cheese contains Propionebacterium freudenreichii (PF) producing the K2-vitamer MK-9(4H) and DHNA in addition to the K2-vitamers found in Norvegia cheese
Study NCT06688032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Norvegia
Description: Cheese with different content of K2 vitamers
Study NCT06099873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
Study NCT06099873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
Study NCT06693427 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Nerve Block
Description: Femoral and Sciatic Nerve Blocks
Study NCT06692777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bergavit
Description: Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
Study NCT06692777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take capsule equivalent amount of maltodextrin for 4 months.
Study NCT06693193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.
Study NCT06692010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexamethasone Solution
Description: 10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
Study NCT06693401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group: PD rehabilitation complemented with Occupational Therapy programme
Description: In intervention group both Physiotherapy and Occupational Therapy programmes were implemented.~Occupational Therapy programme consisted in trainning the amplitude of the movements involved in the realization of each letter of the alphabet separately and through fine motor exercises. Specifically the tasks consisted of performing:~1. 2 types of handwriting exercises, namely for tracing the upper and lower-case letters of the alphabet guided by dotted lines and writing a sentence with and without spatial boundaries, in Portuguese language (to be performed for about 45 minutes, three times a week) and;~2. 4 groups of fine motor tasks exercises, namely for hand manipulation (2 exercises), finger isolation (3 exercises), finger flexion and extension (2 exercises) and coordination (1 exercise). All exercises were performed 10 times, in triplicate, for each hand on a regular basis of 2-3 times per week.
Study NCT06693401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: conventional physiotherapy programme
Description: In this group only the conventional physiotherapy programme was implemented. This programme has the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support. In this regard, participants were guided and supervised in each physiotherapy session by a Parkinson's disease healthcare specialist.
Study NCT06047717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Driving Task
Description: Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon.
Study NCT04770779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching Mitapivat
Description: Tablets
Study NCT04770779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets
Study NCT04770779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat
Description: Tablets
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT06066918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Pregabalin 75 mg twice a day
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05910801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05910801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT05910801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study NCT05910801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06365385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-last meal pattern
Description: Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
Study NCT06365385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-last meal pattern
Description: Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT06365385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-first meal pattern
Description: White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
Study NCT06365385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-first meal pattern
Description: White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
Study NCT04499950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave
Description: Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
Study NCT04499950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: 6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
Study NCT04499950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: 6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
Study NCT06262477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB800
Description: Administered as specified in the treatment arm.
Study NCT06262477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actemra
Description: Administered as specified in the treatment arm.
Study NCT05087875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
Study NCT05087875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The comparison group will be evaluated based on daily self-monitoring data.
Study NCT05420064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm At-risk Relative/ARR Contacts
Description: Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
Study NCT05420064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyGene Portal
Description: Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
Study NCT05420064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will received appropriate clinical care as outline by standard of care guidelines
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241 Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1241 Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT05144815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPC + Exercise protocol
Description: The intervention consists of two parts: IPC and endurance training protocol.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.
Study NCT05144815 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IPC + Exercise protocol
Description: The intervention consists of two parts: sham IPC and endurance training protocol.~Sham IPC: the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.
Study NCT04884698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimit Activator
Description: The Stimit Activator Device is composed of three components.~1. A magnetic stimulator generating current pulses~2. A novel Stimit coil design optimized for phrenic nerve stimulation~3. A coil positioning device for quick, easy and reproducible coil positioning
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT06054815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study NCT05771051 — intervention group
Intervention type: DEVICE
Intervention: Headpulse measurements
Description: Placement of headset on subject
Study NCT05140525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan Tablets
Description: 10 mg oral once daily
Study NCT05140525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: 1 mg to 2.5mg oral three times daily
Study NCT06123468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
Study NCT06282848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 0.05%
Description: Topical application
Study NCT06282848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIMS lens
Description: Spectacle wear
Study NCT06343441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoral scan
Description: intraoral scanning of the edentulous arch and scan body
Study NCT06343441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: open tray impression
Description: conventional method of impression making with silicone rubber material
Study NCT05121870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
Study NCT05121870 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline containing 1% Human serum albumin（solution without UC-MSCs）
Description: 3 does of placebo intravenously at week 0, week 4, week 8.
Study NCT05140525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon pulmonary angioplasty
Description: on hemodynamics and RV function (including advanced assessments of RV-PA coupling
Study NCT05666011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 IPL
Description: IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
Study NCT05091060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS
Description: 56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
Study NCT04922892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Description: Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
Study NCT04922892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroidectomy
Description: Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
Study NCT06554457 — intervention group
Intervention type: DRUG
Intervention: Multimodal analgesia with oral strong opioids
Description: Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
Study NCT06196476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive digital-based educational program
Description: The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session
Study NCT04841226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term indwelling Foley catheter
Description: Foley Catheter inserted for up to 28-days
Study NCT05452564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG Oral Tablet
Description: Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
Study NCT06347471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.
Study NCT06347471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
Study NCT04704960 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Test: liquid biopsy
Description: detection of tumor DNA alteration in cf-DNA
Study NCT06477406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
Study NCT06477406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An active placebo containing supplemental terpenes matched to the high-CBD product.
Study NCT05553561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPRL device
Description: Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
Study NCT05553561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological therapy & Eyelid hygiene
Description: traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
Study NCT06132919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 cream
Description: Topical application
Study NCT06132919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 vehicle
Description: Topical application
Study NCT04809467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.